PharmEasy has closed a funding round of $350 million before filing its Draft Red Herring Prospectus (DRHP) before an Initial Public Offering (IPO). The firm raised about $204 million in funding from Amansa Capital, ApaH Capital, Janus Henderson, OrbiMed, Steadview Capital, ADQ, Neuberger Berman and Sanne Group.

This is the third financing round that the company has closed, bringing the total to $1 billion this year. PharmEasy’s founders, Siddharth Shah, Dhaval Shah, Dhramil Sheth, Harsh Parekh and Hardik Dedhi, have also been granted new stock options before the IPO. Each founder has been given 9,987 stock options under its employee stock ownership plan.

• Just Dial Stocks Skyrocketed 15% On Announcement of Q4FY24 Business and Financial Updates
• Swing-Trading 101: Capturing Market Moves with Flexibility
• Jubilant Pharmova Shares Climbed 8% On Announcing Ceastion of Loss Making Arm’s Operations in Salisbury, USA
• Paytm Shares Gained 4.5% on NPCL’s Approval To Create New VPAs with Axis, HDFC, SBI, and Yes Bank
• Ambuja Cements Shares Gained 3% On Receiving Additional Rs 8,339 Crore Investment From Adani Group

According to the filings, Amansa Capital has invested almost Rs 370 crore, Sanne Group invested more than Rs 443 crore, and Steadview Capital invested Rs 110 crore in the funding. PharmEasy has also added five new independent directors to its board and got board approval to change itself into a public company.